Ainsworth believes a responsible biotech entrepreneur envisions the end goal—acquisition or IPO—from day one. At RetroSense, this meant constantly engaging with potential acquirers like Allergan to understand their needs and generate the specific data required to become an attractive M&A target.
When Sean Ainsworth took over as CEO of Immusoft, he made it a condition that the founding CEO remain with the company for several months. This structured transition was crucial for Ainsworth to understand the complex B-cell therapy modality and ensure a smooth leadership handover.
Before establishing the company, co-founder Sean Ainsworth had to rush to open a bank account to deposit a check from their first customer. This highlights the power of securing market validation and revenue at the absolute earliest stage, even pre-dating formal incorporation.
Immusoft balances its portfolio by internally developing a pipeline of genetically defined orphan disease therapies. Simultaneously, it generates early proof-of-concept data for higher-risk, larger markets like CNS and oncology with the explicit goal of securing strategic partnerships for those assets.
Using safety and preliminary efficacy data from its lead drug for MPS1, Immusoft successfully requested an FDA waiver for definitive toxicology studies for its next program in MPS2. This platform approach saves significant time and capital, accelerating the entire pipeline without 'reinventing the wheel'.
To build a resilient team during a tough economic period, CEO Sean Ainsworth prioritized finding people who deeply understood the 'why' behind the science and its patient impact. This created a committed core team that could navigate funding challenges when capital was scarce for unproven gene therapies.
Founder Sean Ainsworth intentionally started his pioneering AAV gene therapy in an ocular setting before any Western approvals existed. Because an intravitreal injection uses a very small vector amount, it provided a significant safety advantage and a manageable way to prove the technology before attempting systemic delivery.